Synergistic cancer cell killing by the combination of olaparib and PLK1 inhibition, using other small molecules, including BI2536 and BI6727 (volasertib), has been reported in castration-resistant prostate cancer [52] and in HGOC cells with KRAS amplification [53]. Here, KRAS is linked to prostate carcinoma.